louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01049126: Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients
Official title: Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx Assay in Cases With Late Stage Endometrial Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Cancer
Keywords: Late Stage
Lead sponsor: Precision Therapeutics
Sponsor class: INDUSTRY
First posted: 2010-01-14
Enrollment: 76
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Approximately 70 cases of late stage endometrial cancer that have had ChemoFx drug response marker results from August 2007 to January 31, 2009 will be included.

Brief summary: The purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.

Detailed description: This is a multicenter, retrospective chart review study of de-identified drug response marker results and a limited data set of clinical outcome data. Data from approximately 70 cases will be collected from approximately 10 study sites and correlated to the ChemoFx drug response marker results. The outcome of progression free survival will be defined as the period of time between the first dose of chemotherapy following the report of the marker result until clinical progression or death. Objective response will be measured from the first dose of chemotherapy following the report of the marker result until progression or change in therapy. Overall Survival will be measured from the start of chemotherapy to the actual date of death.

Eligibility criteria: Inclusion Criteria:

* Case has an original pathology report showing stage III, IIIa, IIIb, IIIc, IV, IVa, IVb, or recurrent endometrial cancer.
* Case includes a pathology or cytology report from initial diagnosis showing disease of one or more of the following histologic epithelial cell types: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, transitional cell carcinoma, clear cell carcinoma, or adenocarcinoma, not otherwise specified (N.O.S.).
* Case has been identified for pattern of response evaluation.
* Case must have a commercial ChemoFx drug response marker final report.

Exclusion Criteria:

* Cases of patients who were deceased prior to 1 cycle of chemotherapy.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Precision Therapeutics, Inc.
state: Pennsylvania
Study officials:
affiliation: Vice President, Clinical Affairs
name: Holly Gallion, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05595226: Effect of RT3D-TEE-guided Mitral Valve Repair on Outcomes in Patients With Degenerative Mitral Valve Disease
Official title: Effect of RT3D-TEE-guided Mitral Valve Repair on Outcomes in Patients With Degenerative Mitral Valve Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Degenerative Mitral Valve Disease
Lead sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Sponsor class: OTHER
First posted: 2022-10-26
Enrollment: 338
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized controlled trial to investigate the effects of Real-time 3D transesophageal echocardiography (RT3D-TEE)-guided mitral valve repair on surgical failure and 1-year reoccurrence of mitral valve regurgitation in patients with degenerative mitral value disease.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with chronic primary degenerative mitral regurgitation by the preoperative echocardiogram.
* Informed consent was obtained

Exclusion Criteria:

* Re-operation of mitral regurgitation
* Concurrent surgical plan for congenital heart disease, coronary artery bypass grafting, aortic valve surgery, radiofrequency ablation of atrial fibrillation and other cardiac surgeries.
* Mitral valve replacement
* Unable to undergo TEE

Primary outcomes:
measure: Composite events of mitral valve repair failure and 1-year reoccurrence of mitral regurgitation
timeFrame: 1 year
Secondary outcomes:
measure: Individual occurrence of composite endpoints of mitral valve repair failure and 1-year reoccurrence of mitral regurgitation
timeFrame: 1 year
measure: The incidence of secondary transfer, perioperative complications
timeFrame: 1 year
measure: Intraoperative conditions including extracorporeal circulation time, aortic occlusion time
timeFrame: 1 year
measure: The recurrence rate of residual mitral valve regurgitation
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital,Chinese Academy of Medical Sciences
state: Beijing
Study officials:
References:
Clinical trial NCT06366126: Long Term Impact of Child Abuse in University Students
Official title: Long Term Impact of Child Abuse in University Students
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Child Abuse
Lead sponsor: Delta University for Science and Technology
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 242
Sex: ALL
Minimum age (years): 18
Maximum age (years): 23
Standard ages: ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A random sample of 242 participants from university students with history of exposure to child abuse in Al Dakahleya governorate, Egypt, consisted of 151 Males and 91 Females

Brief summary: Based on research and studies, a broad conceptualization of child abuse and neglect has progressively been constructed, defining it as all actions carried out by caregivers that significantly interfere in the child's optimum development and do not adhere to social standards. This conceptualization contemplates aspects such as neglecting physical-biological, cognitive, emotional, and social needs, and the different types of child maltreatment are also classified.

This study aimed too evaluate the psychological and social long-term effects of different types of child abuse.


Eligibility criteria: * Inclusion criteria:

  1. University students passed through the experience of being abused in their childhood
  2. Males and females
  3. Residing in urban or rural area in Al Dakahleya governorate- Egypt
* Exclusion criteria:

  * Individuals with no or questionable history of child abuse

Primary outcomes:
measure: tailored questionnaire
timeFrame: At the baseline of evaluation
Secondary outcomes:
Other outcomes:
Locations:
city: Gamasa
country: Egypt
facility: Amira Hussin Mohammed
Study officials:
References:
Clinical trial NCT05671926: Different Algorithm Models to Predict Postoperative Pneumonia in Elderly Patients
Official title: Different Algorithm Models to Predict Postoperative Pneumonia in Elderly Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Postoperative Pulmonary Complications
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2023-01-05
Enrollment: 10000
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: older patients received general anesthesia in Wuhan Union Hospital from January 1, 2014 to December 31, 2019.

Brief summary: The researchers aim to compare different algorithms to predict postoperative pneumonia in elderly patients and to assess the risk of pneumonia in elderly patients.

Detailed description: Postoperative pneumonia is a common complication that increases the mortality and length of older patients. In order to better assess the risk of postoperative pneumonia in elderly patients, we plan to use database information and different algorithms, such as logistic regression, random forest, and other algorithms respectively to build models and evaluate the effects of the models.

Eligibility criteria: Inclusion Criteria:

1. Age 65 years or older
2. receiving invasive ventilation during general anesthesia for surgery

Exclusion Criteria:

1. preoperative mechanical ventilation
2. procedures related to a previous surgical complication
3. a second operation after surgery
4. organ transplantation
5. discharged within 24 hours after surgery
6. cardiac and thoracic surgery

Primary outcomes:
measure: Postoperative pulmonary complications
timeFrame: within one week after surgery
Secondary outcomes:
measure: Postoperative pulmonary complications
timeFrame: 30 days after surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00726726: Drug Interaction Study With a Potential Alzheimer's Disease Compound
Official title: Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer Disease
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2008-08-01
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects
* 18-45 yrs old inclusive

Exclusion Criteria:

* Women

Primary outcomes:
measure: Pharmacokinetic effects of BMS-708163 on interacting drugs (midazolam, warfarin, caffeine, omeprazole, and dextromethorphan)
timeFrame: throughout the study
Secondary outcomes:
measure: Safety variables (adverse events, vital signs, safety labs)
timeFrame: throughout the study
Other outcomes:
Locations:
city: Hamilton
country: United States
facility: Bristol-Myers Squibb Clinical Pharmacology Unit
state: New Jersey
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT05636826: Olive Leaf Extracts in the Control of Hypertension
Official title: Efficacy of a Treatment Based on Olive Leaf Extracts in the Control of Cardiovascular Risk Factors:Hypertension
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Hypertension
Keywords: hypertension
Lead sponsor: University of Monastir
Sponsor class: OTHER
First posted: 2022-12-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).

Patients over 18 years of age with:

Arterial hypertension (hypertension).

Detailed description: This study will be carried out in 2 emergency departments (at the exit of the emergency room, patients included in the GR2 study) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital).

All the population will benifit of a biological assessment which include:

Complete lipid profile, blood sugar, creatinine

one population will be randomized:

The population of patients with hypertension.

For patients in the hypertension group:

A blood pressure with holter will be carried out for 24 hours .

Eligibility criteria: Inclusion Criteria:

* patients over 18 years of age with:

Arterial hypertension (hypertension)

Exclusion Criteria:

* . Exclusion criteria: None.

Primary outcomes:
measure: rate of blood pressure reduction
timeFrame: 90 days
Secondary outcomes:
measure: rate of lipid balance variation The secondary endpoint
timeFrame: 90 days
Other outcomes:
Locations:
city: Monastir
country: Tunisia
facility: University Hospital Fattouma Bourguiba Monastir
Study officials:
References:
Clinical trial NCT06970626: Quality of Recovery in Laparoscopic Sleeve Gastrectomy Using Dexmedetomidine Infusion Versus Laparoscopic TAP Block in Combination With Paragastric Neural Block
Official title: Quality of Recovery in Laparoscopic Sleeve Gastrectomy Using Dexmedetomidine Infusion Versus Laparoscopic TAP Block in Combination With Paragastric Neural Block
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Laparoscopic Sleeve Gastrectomy
Keywords: dexmedetomidine
Laparoscopic Sleeve Gastrectomy (LSG)
Paragastric Neural Block
Laparoscopic TAP
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-05-14
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn which is better, combining Dexmedetomidine infusion and paragastric neural block or combining laparoscopic TAP block and paragastric neural block to enhance recovery after laparoscopic sleeve gastrectomy.

The main questions it aims to answer are:

Will using paragastric neural block (PGNB) combined with dexmedetomidine infusion give better recovery or using PGNB combined with laparoscopic transversus abdominis plane (LTAP) block in patients undergoing laparoscopic sleeve gastrectomy.

This will be assessed by:

Recording how much opioids were consumed by the patients Hemodynamic stability of the enrolled patients Pain scores as given by the patient The quality of postoperative patient recovery How many patients encountered nausea or vomiting


Eligibility criteria: Inclusion Criteria:

1. American Society of Anesthesiologists (ASA) physical status II- III
2. BMI 35- 50 kg/m2

Exclusion Criteria:

1. Significant hepatic, renal, neuromuscular, or cardiac impairments
2. Extreme obesity (BMI \> 50 kg/m2)
3. Patients on current opioid medication
4. Allergies to dexmedetomidine or bupivacaine

Primary outcomes:
measure: Opioid Consumption
timeFrame: Opioid consumption will be measured at 4, 8, and 12 hours postoperatively
measure: Patient satisfaction using the QoR 40 questionnaire
timeFrame: Postoperative day 1
Secondary outcomes:
measure: Heart Rate
timeFrame: Heart rate will be monitored continuously every 5 minutes and will be recorded prior to induction, post-induction, after the loading dose of dexmedetomidine, 4 hours and 12 hours postoperatively.
measure: Time to mobilize
timeFrame: Postoperative day 1
measure: Incidence of nausea and vomiting
timeFrame: Postoperative day 1
measure: Baseline demographics
timeFrame: preoperatively
measure: Blood Pressure
timeFrame: Blood pressure will be monitored continuously every 5 minutes and will be recorded prior to induction, post-induction, after the loading dose of dexmedetomidine, 4 hours and 12 hours postoperatively.
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Main University Hospital
Study officials:
References:
Clinical trial NCT03697226: Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.
Official title: An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HSIL of Cervix
HSIL, High Grade Squamous Intraepithelial Lesions
High-Grade Cervical Intraepithelial Neoplasia
Human Papilloma Virus
HIV Negative
Cervical Cancer
CIN - Cervical Intraepithelial Neoplasia
Cervical Neoplasm
Cervical Dysplasia
Lead sponsor: Antiva Biosciences
Sponsor class: INDUSTRY
First posted: 2018-10-05
Enrollment: 8
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.


Eligibility criteria: Inclusion Criteria:

1. Women, 25 to 50 years old.
2. Biopsy-confirmed cervical HSIL that is p16+ within 60 days of enrollment (dosing) with no evidence of invasive cancer in any specimen.
3. Colposcopy is satisfactory based on visualization of the entire squamo-columnar junction (SCJ). The borders of all lesions must be completely visible.
4. The upper limit of the visible (usually aceto-white) lesion is within 3 quadrants or less at screening.

Exclusion Criteria:

1. Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females.
2. HIV positive (tested at screening visit or within 3 months of screening visit).
3. Resolution of visible CIN lesion prior to enrollment.
4. ECC positive for glandular disease (adenocarcinoma in situ) or invasive cancer.
5. History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of CIN, or hysterectomy.

Primary outcomes:
measure: Safety & Tolerability of ABI-1968 for the treatment of cHSIL
timeFrame: 42 days
Secondary outcomes:
measure: Systemic exposure to ABI-1968 Topical Cream following topical application to the cervix.
timeFrame: 42 days
Other outcomes:
measure: Histopathology of areas with biopsy-proven disease
timeFrame: 42 days
measure: Changes in HPV viral load following multiple doses of ABI-1968 Topical Cream
timeFrame: 42 days
Locations:
city: Bloemfontein
country: South Africa
facility: Research Center
state: Free State Province
Study officials:
References:
Clinical trial NCT03052426: Occupational Therapy's Role in Promoting Community Wellness Utilizing Sit-Stand Workstations
Official title: Occupational Therapy's Role in Promoting Community Wellness: A Multi-modal Approach to Combat Sedentary Behavior in the Workplace Utilizing Sit-Stand Workstations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Pain
Musculoskeletal Strain
Sedentary Lifestyle
Lead sponsor: West Virginia University
Sponsor class: OTHER
First posted: 2017-02-14
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to combat the growing global health issue of sedentary behavior and the associated health consequences of prolonged sitting in the workplace. The population of desk-based workers makes up a relatively large population and are an important target for this health promoting initiative with a focus on improving posture, encouraging movement, and fostering a more active and healthy business community. It's important to recognize that occupational therapy practitioners can contribute to community health promotion/disease prevention programs by the skill-set of practitioners to understand habits and routines that influence the adoption and maintenance of healthy behaviors.


Eligibility criteria: Inclusion Criteria:

* Participants must spend \> 50% of their work day seated at the computer
* Participants must be primarily English speaking
* Participants must work within the Health Sciences Center building at West Virginia University

Exclusion Criteria:

* Participants who are less than 18 years of age
* Participants who are not primarily English speaking
* Participants who spend \<50% of their work day seated at the computer
* Participants who do not work within the Health Sciences Center building at West Virginia University
* Participants who are pregnant

Primary outcomes:
measure: Reported Musculoskeletal Discomfort Per Group at 3 Months
timeFrame: 3 months
measure: Reported Musculoskeletal Discomfort Per Group at 6 Months
timeFrame: 6 months
Secondary outcomes:
measure: Reported Musculoskeletal Discomfort at Work at 3 Months and 6 Months All Groups Combined
timeFrame: Beginning of study, 3 months, and 6 months (end of study)
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: West Virginia University
state: West Virginia
Study officials:
affiliation: West Virginia University
name: Brandy Brown, OTD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03274726: Iron Status of Women and Young Children in the United States
Official title: Iron Status of Toddlers, Non-pregnant, and Pregnant Women in the United States
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iron-deficiency
Nutritional Deficiency
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2017-09-07
Enrollment: 5000
Sex: ALL
Minimum age (years): 12
Maximum age (years): 49
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: NHANES is a nationally-representative, cross-sectional study of nutrition and health for individuals residing in the U.S.

Brief summary: This analysis describes the distribution of TBI and the prevalence of iron deficiency (ID) and iron deficiency anemia (IDA) among toddlers, non-pregnant women, and pregnant women.

Detailed description: Background: Total body iron stores (TBI), which are calculated from serum ferritin (SF) and soluble transferrin receptor (sTfR) concentrations, can be used to assess the iron status of populations in the United States.

Objective: This analysis describes the distribution of TBI and the prevalence of iron deficiency (ID) and iron deficiency anemia (IDA) among toddlers, non-pregnant women, and pregnant women.

Design: Investigators analyzed data from NHANES; toddlers aged 12-23 mo (NHANES 2003-2010), non-pregnant women aged 15-49 y (NHANES 2007-2010), and pregnant women aged 12-49 y (NHANES 1999-2010). Investigators used SAS survey procedures to plot distributions of TBI and produce prevalence estimates of ID and IDA for each target population. All analyses were weighted to account for the complex survey design

Eligibility criteria: Included:

* Children ages 12-23 months and Women ages 12-49 years
* Those who completed the MEC

Excluded:

- Those missing data on iron biomarkers

Primary outcomes:
measure: Iron Deficiency
timeFrame: 1999-2010
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant females, and pregnant females in the United States. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1640S-1646S. doi: 10.3945/ajcn.117.155978. Epub 2017 Oct 25.